Swog Cancer Research Network

This large phase 3 trial tests whether a different strain of BCG (a bacteria that boosts the immune system) or adding a BCG skin shot before the standard bladder treatment can better prevent high-grade bladder cancer from coming back. About 1000 patients with early-stage bladder …

This study tested whether adding the drug everolimus to standard hormone therapy for one year helps prevent breast cancer from coming back in people with high-risk, hormone receptor-positive, HER2-negative breast cancer. About 1,900 participants were randomly assigned to receive …

This study tests a combination of the targeted drug amivantamab plus two chemotherapy drugs (carboplatin and paclitaxel) in 50 adults with head and neck cancer that has come back or spread. Participants have already tried a PD-1 inhibitor. The goal is to see if the combination ca…

This study tests whether a special nutrition drink, given before and after bladder removal surgery, can boost the immune system and reduce problems like infections. About 200 adults with bladder cancer are taking part. The goal is to see if better nutrition leads to fewer complic…

This phase 3 study tests whether adding daratumumab to lenalidomide after a stem cell transplant helps people with multiple myeloma live longer without the disease getting worse. About 1,100 participants receive either lenalidomide alone or lenalidomide plus daratumumab for up to…

This study tests a drug called sacituzumab govitecan in 44 people with HER2-negative breast cancer that has spread to the brain. The drug works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. The goal is to see if it can shrink brain tum…

This study tested whether adding cetuximab to the standard drug afatinib helps people with advanced EGFR-mutant lung cancer live longer. 174 newly diagnosed patients received either the combination or afatinib alone. The main goal was to see if more patients were alive after two …

This phase 3 trial compares a combination of two drugs (ramucirumab and pembrolizumab) against standard chemotherapy for people with stage IV or recurrent non-small cell lung cancer whose disease worsened after initial immunotherapy. About 838 participants will be randomly assign…

This study tests whether adding ruxolitinib to standard CML medications (like dasatinib or nilotinib) can further reduce the number of leukemia cells in patients who still have detectable disease. About 81 adults with chronic-phase CML will receive either their usual drug alone o…

This study tests whether adding a new drug called asciminib to standard treatment works better for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). About 55 adults will receive a combination of asciminib, dasatinib, prednisone, …

This study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The drug targets this change to stop cancer growth. About 116 participants will receive the treatment to see if it shrinks tumors and how safe it is.

This study tests whether taking two drugs, eflornithine and sulindac, together can prevent new high-risk polyps or second colon cancers in people who have already been treated for stage 0 to III colon or rectal cancer. About 354 participants will take the drug combination or a pl…

This study tests whether a financial navigation program can reduce money-related stress for cancer patients and their caregivers. About 331 adults with advanced cancer or blood cancers will receive either financial coaching or usual care. The goal is to see if this help lowers fi…

This study tests whether regularly checking in on symptoms, along with providing educational materials, helps young women (ages 18-44) with early-stage hormone-positive breast cancer continue taking their hormone therapy as prescribed. Many women stop these pills early due to sid…

This study follows over 1,300 people with breast, lung, or ovarian cancer who are starting a type of chemotherapy called taxane. The goal is to find out which patients are more likely to develop nerve damage (peripheral neuropathy), which can cause tingling or numbness in the han…

This study tests online decision-support tools for women with atypical hyperplasia or lobular carcinoma in situ, conditions that raise breast cancer risk. About 412 women and their doctors will use these tools to help make informed choices about chemoprevention (medication to low…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will take part, and their doctors will either use the t…

This study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers are collecting blood samples from 956 newly diagnosed patients and tracking their health over time. The goal is to see if this…